Article
A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects.
Biotherapy (Dordrecht, Netherlands) - 1 Jan 1991
Yano T, Ishida T, Yoshino I, Murata M, Yasumoto K, Kimura G, Nomoto K, Sugimachi K
Abstract excerpt
We designed a unique regimen of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and recombinant interleukin 2 (rIL-2) for application with surgical adjuvant therapy of cancer. The regimen features the prolonged (6 consecutive days) s.c. administration of low-dose rIL-2 and the transfer of ex vivo generated LAK cells from regional lymph node lymphocytes, obtained at the time of surgical...
Topics
- Adjuvants, Immunologic
- Aged
- Cell Survival
- Combined Modality Therapy
- Culture Media
- Female
- Humans
- Immunotherapy, Adoptive
- Interleukin-2
- Killer Cells, Lymphokine-Activated